Royal Oak, MINCT07006727Now EnrollingIRB Ready

Small Cell Lung Carcinoma Clinical Trial in Royal Oak, MI

Access cutting-edge small cell lung carcinoma treatment through this clinical trial at a research site in Royal Oak. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Royal Oak location

Preparing your pre-screening questions…

Expert Care in Royal Oak

Access small cell lung carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related small cell lung carcinoma treatment provided free

Apply for This Royal Oak Location

Check if you qualify for this small cell lung carcinoma clinical trial in Royal Oak, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Royal Oak

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Royal Oak site if eligible
  4. 4Begin participation

About This Small Cell Lung Carcinoma Study in Royal Oak

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Age ≥ 18 years old
Patients with one of the following indications:
Locally advanced, unresectable, or metastatic SCLC with disease progression following, or intolerance to, at least 1 line of systemic therapy, including platinum-containing chemotherapy, unless patient was ineligible to receive such therapy. Prior DLL3-targeted therapy is allowed. For dose expansion, patients should have received no more than 2 prior lines of systemic therapy.
Dose escalation only: LCNEC of the lung with disease progression following, or intolerance to, at least 1 line of systemic therapy, including platinum-containing chemotherapy, unless patient was ineligible to receive such therapy.
Dose expansion only: Locally advanced, unresectable, or metastatic de novo or castration-resistant, treatment-emergent NEPC with neuroendocrine differentiation confirmed by local histology and NEPC marker expression (e.g., chromogranin, synaptophysin) confirmed by local IHC. Prior PSMA-targeted, Lu-177-based RLT is allowed. Patients must have at least one measurable lesion (per RECIST 1.1) that shows 111In-ETN029 uptake higher than surrounding tissues on SPECT/CT as assessed by the Investigator.
Dose expansion only: Locally advanced, unresectable, or metastatic GEP-NEC with disease progression following, or intolerance to, at least 1 line of systemic therapy, including platinum-containing chemotherapy, unless patient was ineligible to receive such therapy. Patients must have at least one measurable lesion (per RECIST 1.1) that shows 111In-ETN029 uptake higher than surrounding tissues on SPECT/CT as assessed by the Investigator.

Exclusion Criteria

Absolute neutrophil count (ANC) \< 1.0 x 109/L, hemoglobin \< 9 g/dL, or platelet count \< 75 x 109/L
QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
eGFR \< 60 mL/min (\<0.835 mL/s), calculated using the CKD-EPI 2021 formula or measured
Unmanageable urinary tract obstruction or urinary incontinence
Presence of leptomeningeal disease, of symptomatic CNS metastases or of CNS metastases that require local CNS-directed therapy
History of or current interstitial lung disease or pneumonitis ≥ Grade 2
Any prior DLL3-targeted therapy (except for SCLC) and any prior RLT (except for NEPC) Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Royal Oak?

Yes, this clinical trial (NCT07006727) has an active research site in Royal Oak, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Small Cell Lung Carcinoma Treatment Options in Royal Oak, MI

If you're searching for small cell lung carcinoma treatment options in Royal Oak, MI, this clinical trial (NCT07006727) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Royal Oak research site is actively enrolling participants for this clinical trial. You'll receive care from experienced small cell lung carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all small cell lung carcinoma clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Royal Oak, MI

See all lung cancer clinical trials recruiting in Royal Oak — not just this study.

Browse Lung Cancer Trials in Royal Oak →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Royal Oak?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Royal Oak, MI